Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 5/20 | 0.42 |
| ▸ | FLT3 | P36888 | 4/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | CDK1 | P06493 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | STK4 | Q13043 | 1/20 | 0.36 |
| ▸ | STK3 | Q13188 | 1/20 | 0.36 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.36 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.36 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCND2 | P30279 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | PAK3 | O75914 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16309174 | 0.90 | PAK1 (0.43) | TNK2PAK1CDK2SRCCDK4 | |
| SCHEMBL15041890 | 0.88 | TNK2 (0.40) | TNK2FLT3PAK1CDK2KDR | |
| SCHEMBL15036149 | 0.87 | TNK2 (0.41) | TNK2FLT3PAK1CDK2KDR | |
| SCHEMBL15785331 | 0.86 | TNK2 (0.46) | TNK2FLT3PTK2PAK1SRC | |
| SCHEMBL15041669 | 0.85 | PTK2 (0.43) | TNK2PTK2 | |
| SCHEMBL15036037 | 0.84 | TNK2 (0.41) | TNK2PTK2 | |
| SCHEMBL13553812 | 0.82 | TNK2 (0.43) | TNK2FLT3PTK2PAK1SRC | |
| SCHEMBL15036132 | 0.81 | TNK2 (0.41) | TNK2SRCCDK4CCND1CCND2 | |
| SCHEMBL16309202 | 0.79 | PAK1 (0.45) | TNK2PAK1CDK2SRCCDK4 | |
| SCHEMBL15036084 | 0.78 | TNK2 (0.43) | TNK2SRCCDK4CCND1CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | TNK2 14/4885FLT3 803/4885PTK2 137/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885FLT3 811/4885PTK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.